Audentes Therapeutics, Inc
BOLD
BOLD was delisted on the 14th of January, 2020.
57 hedge funds and large institutions have $283M invested in Audentes Therapeutics, Inc in 2016 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 5 closing their positions.
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
16% more funds holding
Funds holding: 49 → 57 (+8)
4% more capital invested
Capital invested by funds: $272M → $283M (+$10.8M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
Top Buyers
Top Sellers
BOLD Hedge Fund Activity: Q4 2016 in Review
57 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q4 2016, worth a combined $283M — up 4% from $272M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new BOLD positions and 5 closed out — a net gain of 8 holders — while 13 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $5.61M. The largest seller was RA Capital Management, cutting an estimated $3.02M.
- 57 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q4 2016, up from 49 in Q3 2016.
- Funds reported $283M of Audentes Therapeutics, Inc stock for Q4 2016, up 4% quarter-over-quarter.
- 13 funds opened new Audentes Therapeutics, Inc positions in Q4 2016 and 5 closed out, a net change of +8 holders.
- The largest Audentes Therapeutics, Inc buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $5.61M added.
- The largest Audentes Therapeutics, Inc seller in Q4 2016 was RA Capital Management, an estimated $3.02M sold.
Based on aggregated 13F filings for Q4 2016.